Examination of the effect of a combination of benzbromarone and febuxostat in patients with hyperuricemia complicating diabetic nephropathy
Not Applicable
Recruiting
- Conditions
- hyperuricemia Diabetes
- Registration Number
- JPRN-UMIN000012628
- Lead Sponsor
- Gifu University hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients contraindicated for benzbromarone, including 1) patients with hepatic disorders [ALT (GPT) ≥ 100 IU/L], 2) patients with renal calculus and/or with severe renal function impairment (diabetic nephropathy stage 4 or more severe), 3) pregnant or possibly pregnant women, and 4) patients with a history of hypersensitivity to any ingredient of the product; (2) Patients contraindicated for febuxostat, including 1) patients with a history of hypersensitivity to any ingredient of the product and 2) patients on treatment with mercaptopurine hydrate or azathioprine; and (3) Other patients judged inappropriate by the physician in charge.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement of hyperuricemia
- Secondary Outcome Measures
Name Time Method